Influenza Drug Market Report 2025

The influenza drug market size has grown strongly in recent years. It will grow from $0.98 billion in 2024 to $1.04 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth observed during the historic period can be attributed to the increasing frequency of seasonal influenza outbreaks, rising healthcare expenditure, growing public awareness of vaccination, expanded use of antiviral drugs, and the implementation of government immunization programs.

The influenza drug market size is expected to see strong growth in the next few years. It will grow to $1.32 billion in 2029 at a compound annual growth rate (CAGR) of 6%. The anticipated growth in the forecast period can be linked to the rising prevalence of influenza-like illnesses, improved global healthcare access, expansion of healthcare infrastructure in emerging markets, increasing demand for combination therapies, and a stronger emphasis on preventive healthcare. Key trends expected in the forecast period include innovations in vaccine development, advancements in diagnostic technologies, development of next-generation antivirals, progress in antiviral research, and improvements in drug delivery systems.

The rising incidence of influenza infections is expected to drive growth in the influenza drug market in the coming years. Influenza is a contagious respiratory illness caused by influenza viruses, producing symptoms such as fever, cough, sore throat, and body aches. The increasing incidence of influenza infections is driven by frequent viral mutations, which reduce vaccine effectiveness and heighten population vulnerability to outbreaks. Influenza drugs help control the spread of infections and reduce disease severity, providing essential treatment options for affected individuals. For example, in September 2023, the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, reported that during the 2022-2023 season, influenza virus infections in the United States led to an estimated 31 million symptomatic illnesses, 14 million medical visits, 360,000 hospitalizations, and 21,000 deaths. Consequently, the growing incidence of influenza infections is propelling demand for influenza drugs.

Companies in the influenza drug market are also advancing treatment technologies to improve patient outcomes and compliance. Innovations in drug formulation, for instance, allow active pharmaceutical ingredients to be combined with excipients to create medications with enhanced properties. In August 2024, F. Hoffmann-La Roche Ltd., a Switzerland-based pharmaceutical company, launched Baloxavir Marboxil for Suspension, a strawberry-flavored, single-dose oral antiviral designed specifically for children. The formulation allows for accurate weight-based dosing, making home administration easier and improving adherence. While this innovation enhances pediatric influenza treatment and ease of use, resistance may still emerge over time, particularly in young patients.

In July 2024, GlaxoSmithKline plc (GSK), a Netherlands-based pharmaceutical company, partnered with CureVac N.V., a Germany-based biotechnology company, to advance mRNA vaccine development. Through this collaboration, GSK aims to accelerate the development of COVID-19 and influenza vaccine candidates, strengthen its mRNA vaccine platform, and expand its infectious-disease pipeline.

Major players in the influenza drug market are F. Hoffmann-La Roche Ltd., Pfizer Inc., AstraZeneca PLC, GlaxoSmithKline plc, Daiichi Sankyo Co. Ltd., Moderna Inc., BioNTech SE, Shionogi & Co. Ltd., Green Cross Corp, Emergent BioSolutions Inc., Novavax Inc., Hualan Biological Engineering Inc., Serum Institute of India Pvt. Ltd., CSL Seqirus Pty Ltd., BioCryst Pharmaceuticals, Inc., SAB Biotherapeutics Inc., Viriom Inc., Osivax SAS, Cocrystal Pharma Inc., Sinovac Biotech Ltd.

North America was the largest region in the influenza drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in influenza drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the influenza drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

An influenza drug is a medication designed to prevent or treat influenza (flu) by targeting the influenza virus. These drugs function through various mechanisms, including inhibiting viral replication, preventing viral entry into host cells, or enhancing the immune response against the virus.

The main categories of influenza drugs are influenza A, influenza B, and influenza C. Influenza A infects humans and multiple animal species, causing seasonal flu outbreaks and occasionally pandemics. Administration routes include oral, intranasal, intravenous, intramuscular, and subcutaneous delivery. These drugs are distributed through hospital pharmacies, retail pharmacies, and online pharmacies and comprise classes such as neuraminidase inhibitors, cap-dependent endonuclease inhibitors, fusion inhibitors, M2 ion channel inhibitors, host cell protease inhibitors, immunomodulatory agents, RNA polymerase inhibitors, hemagglutinin stem binders, cytokine inhibitors, and host factor-targeting agents. End users include hospitals and clinics, pharmacies, vaccination centers, research institutions, government health agencies, long-term care facilities, community health centers, and corporate health programs.

The influenza drug market research report is one of a series of new reports that provides influenza drug market statistics, including influenza drug industry global market size, regional shares, competitors with a influenza drug market share, detailed influenza drug market segments, market trends and opportunities, and any further data you may need to thrive in the influenza drug industry. This influenza drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The influenza drug market consists of sales of oseltamivir phosphate, rimantadine, zanamivir, baloxavir marboxil and favipiravir (avigan or fabiflu). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.